biostudies-literatureUnknown43Scholl S<h4>Background</h4>There is a lack of information as to which molecular processes, present at diagnosis, favor tumour escape from standard-of-care treatments in cervical cancer (CC). RAIDs consortium (www.raids-fp7.eu), conducted a prospectively monitored trial, [BioRAIDs (NCT02428842)] with the objectives to generate high quality samples and molecular assessments to stratify patient populations and to identify molecular patterns associated with poor outcome.<h4>Methods</h4>Between 2013 and 2017, RAIDs collected a prospective CC sample and clinical dataset involving 419 participant patients from 18 centers in seven EU countries. Next Generation Sequencing has so far been carried out on a total of 182 samples from 377 evaluable (48%) patients, allowing to define dominant genetic alterationsEBioMedicine253-260https://www.ebi.ac.uk/biostudies/studies/S-EPMC6562019biostudies-literatureClinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.PMC6562019Samet NMorice PCampo ERDDeutsch EHupe PKereszt ABalint BZijlmans HJordanova EDema AKerr CFabbro MNgo CDema SGestraud PKoprivsek KServant NGuyon FHillemanns PLecuru FFeron JGBerns ECoutant CKenter Gde la Rochefordiere AFloquet AMinsat MSavignoni ADureau SPopovic MGleeson NGarbay DNagy IFourchotte VClasse JMMargan MCraina MColombo PEMesgouez-Nebout NKamal MRouzier RDjuran BMarchal FSaint-Jorre NMalenkovic GWimberger PFumoleau Pde Koning LScholl SMandic ASamuels SGirard Evon der Leyen HDubot CfalseClinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.<h4>Background</h4>There is a lack of information as to which molecular processes, present at diagnosis, favor tumour escape from standard-of-care treatments in cervical cancer (CC). RAIDs consortium (www.raids-fp7.eu), conducted a prospectively monitored trial, [BioRAIDs (NCT02428842)] with the objectives to generate high quality samples and molecular assessments to stratify patient populations and to identify molecular patterns associated with poor outcome.<h4>Methods</h4>Between 2013 and 2017, RAIDs collected a prospective CC sample and clinical dataset involving 419 participant patients from 18 centers in seven EU countries. Next Generation Sequencing has so far been carried out on a total of 182 samples from 377 evaluable (48%) patients, allowing to define dominant genetic alterations2019-01-01T00:00:00Z2019 May2026-05-07T01:40:52.95Z2019-07-24T07:15:57ZS-EPMC65620193095261910.1016/j.ebiom.2019.03.069